Eli Lilly and Co
Treasury yields fall as traders continue on to evaluate potential clients of futures Fed level cuts
The 10-12 months U.S. Treasury produce retreated on Tuesday, reversing training course from the former day’s trade and continuing a basic downward craze about the past 7 days. The produce on the benchmark 10-12 months take note was down 5 basis factors at 3.907%, having fallen below 4% on Thursday to strike its least expensive […]
Read More
The weight loss drug boom isn't over yet — here's what to expect in the year ahead
George Frey | Bloomberg | Getty Images Weight loss drugs exploded into the public eye this year, and 2024 will bring more change to the evolving market. The drugs skyrocketed in popularity in 2023 as they helped patients shed significant weight, despite hefty price tags, mixed insurance coverage and a handful of unpleasant side effects. […]
Read More
Prescriptions for Eli Lilly’s new weight-loss drug get off to a strong start and confirm bright outlook
The launch of Eli Lilly ‘s weight-loss drug Zepbound — a key pillar of our investment thesis in the pharmaceuticals giant — is going swimmingly in the U.S., Jefferies said Friday. Weekly Zepbound prescriptions totaled 7,700 in the week ended Dec. 8, its fourth on the U.S. market, according to Jefferies, which cited data compiled […]
Read More
Is Novo Nordisk a get? Wall Avenue banking companies weigh in — and one offers it 36% draw back
For a lot of traders, the pounds loss drug boom has boosted Danish pharmaceutical big Novo Nordisk ‘s appeal this calendar year — but just one financial investment bank has reservations. “Above the coming yr, we envisage sentiment to change, most likely originally as a final result of the launch of competitor Eli Lilly ‘s […]
Read More
If you can't build the next Ozempic, buy it: Where M&A could be heading in the obesity drug space
Investors are contemplating where and when the next big obesity drug deal will occur. At the moment, Novo Nordisk and Eli Lilly have the growing obesity drug market all to themselves. But given the potential size of this opportunity, which some have put at more than $100 billion by 2030 , other pharmaceuticals companies — […]
Read More
Weight gain after stopping Eli Lilly's new obesity treatment should help, not hurt the stock
Some Eli Lilly investors appear concerned about clinical trial data that showed patients regained weight after they stopped taking the company’s obesity drug Zepbound. The situation seems rather clear-cut to us: It’s no reason to sell. Eli Lilly shares on Tuesday shook off afternoon losses to close higher by 0.12%, at $584.76 each — a […]
Read More
Patients regain weight after stopping Eli Lilly's Zepbound, study says
Eli Lilly’s drug tirzepatide was approved for weight loss by the FDA. Courtesy of Eli Lilly Patients who took Eli Lilly‘s weight loss drug Zepbound regained around half the weight they shed after stopping the newly approved treatment for a year, according to data released Monday. The data, which represents the full results from an […]
Read More
Treasury yields inch increased in advance of Fed meeting
U.S. Treasury yields have been fractionally better on Monday, as investors appear ahead to this week’s Federal Reserve policy meeting. The yield on the benchmark 10-calendar year Treasury observe was just in excess of a solitary foundation stage higher at 4.2563%, although the produce on the 30-yr Treasury bond was just underneath a level greater […]
Read More
Investing in Space: Why Amazon bought rocket launches from rival SpaceX
United Launch Alliance Atlas V rocket carrying the first two demonstration satellites for Amazon’s Project Kuiper broadband internet constellation stands ready for launch on pad 41 at Cape Canaveral Space Force Station on October 5, 2023 in Cape Canaveral, Florida, United States. Paul Hennessey | Anadolu Agency | Getty Images CNBC’s Investing in Space newsletter […]
Read More
Biden administration asserts ability to seize drug patents in shift to slash significant charges
President Joe Biden speaks about guarding Social Protection, Medicare, and lowering prescription drug expenditures, during a stop by to OB Johnson Park and Local community Centre, in Hallandale Beach front, Florida, on Nov. 1, 2022. Kevin Lamarque | Reuters The Biden administration on Thursday asserted its authority to seize the patents of sure highly-priced prescription […]
Read More